Pharmaron Beijing Co (300759) Fair Value & Analysis
Healthcare · CN · Market cap 40.4B CNY
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 7 days ago
Share price +15.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ¥17.77 – ¥29.37 · fair‑value band ¥13.52 – ¥30.97 · the ¥23.67 price screens below the ¥24.78 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Pharmaron Beijing Co (300759) currently trades at ¥23.67, while our model-based Fair Value estimate is ¥24.78 — implying the stock looks roughly 4.7% undervalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Pharmaron Beijing Co generated revenue of 14.6B CNY at a net margin of 11.6%. Revenue grew 15.5% year over year. It earns a return on equity of 10.0%. Net debt stands at 2.0B CNY. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Pharmaron Beijing Co reported revenue of ¥14.1B in FY2025 versus ¥7.4B in FY2021, a compound +17.3%/yr. Reported net income was ¥1.7B in FY2025, compounding +0.0%/yr from FY2021.
Is 300759 fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 4,803 MXN | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Pharmaron Beijing Co (300759) undervalued?
What is the fair value of 300759?
What is the quality score of 300759?
What is the revenue of Pharmaron Beijing Co (300759)?
What is the net profit margin of 300759?
Does Pharmaron Beijing Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.